Literature DB >> 3863794

Renal tolerance of imipenem/cilastatin and other beta-lactam antibiotics in rats.

K Sack, J Herhahn, R Marre, E Schulz.   

Abstract

Imipenem is inactivated by the renal dehydropeptidase I, which can be inhibited by cilastatin. Therefore, both compounds are administered in combination. According to the manufacturers, they are not nephrotoxic in rats. 70 female Wistar rats (n = 10/test series) were treated over five days at dosage intervals of 12 hours with intraperitoneal injections (injection volume: 10 ml/200 g body weight) of isotonic 0.9% NaCl, cilastatin (1000 mg/kg/day), imipenem (500 and 1000 mg/kg/day), cilastatin + imipenem (500 or 1000 mg/kg/day each) and cefsulodin (1000 mg/kg/day). The nocturnal excretion of renal tubular cells was determined. Furthermore, three rats in each test were treated intraperitoneally with 150 mg/kg imipenem or with the combination of imipenem and cilastatin (150 mg/kg each). Imipenem concentrations were measured over four hours in the blood of the tail vein. Commencing on the second day of study, cilastatin, imipenem and the combination of both substances induced significant surplus excretion of tubular cells compared to the control group. The tubulotoxic effects of imipenem and imipenem + cilastatin in combination were dose-dependent. The toxic effects of imipenem, imipenem + cilastatin and cefsulodin did not significantly differ. Cilastatin prolonged the half-life of imipenem in the blood from 0.4 to 0.9 h and increased the AUC of imipenem from 156 to 325 mg/l/h.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3863794     DOI: 10.1007/bf01644239

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  6 in total

1.  Experimental investigations of cefuroxime in renal tolerance and therapeutic efficacy in pyelonephritis.

Authors:  K Sack; H Freiesleben; E Schulz; R Marre; W Henkel
Journal:  Proc R Soc Med       Date:  1977

2.  Mechanisms of cephalosporin nephrotoxicity: a comparison of cephaloridine and cephaloglycin.

Authors:  B M Tune; D Fravert
Journal:  Kidney Int       Date:  1980-11       Impact factor: 10.612

3.  A randomized study comparing clinical efficacy and safety of thienamycin formamidine (MK0787)/renal dipeptidase inhibitor (MK0791) and cefazolin.

Authors:  B S Ribner; R Raeder; M Hollstein; E H Freimer
Journal:  J Antimicrob Chemother       Date:  1983-10       Impact factor: 5.790

4.  Imipenem/cilastatin.

Authors:  M Barza
Journal:  Eur J Clin Microbiol       Date:  1984-10       Impact factor: 3.267

5.  A multiclinic randomized study of the comparative efficacy, safety and tolerance of imipenem/cilastatin and moxalactam.

Authors:  G B Calandra; M Hesney; C Grad
Journal:  Eur J Clin Microbiol       Date:  1984-10       Impact factor: 3.267

6.  Ceftazidime and renal function.

Authors:  K Alestig; B Trollfors; R Andersson; L Olaison; M Suurküla; S R Norrby
Journal:  J Antimicrob Chemother       Date:  1984-02       Impact factor: 5.790

  6 in total
  2 in total

Review 1.  Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  S P Clissold; P A Todd; D M Campoli-Richards
Journal:  Drugs       Date:  1987-03       Impact factor: 9.546

2.  Cilastatin protects against imipenem-induced nephrotoxicity via inhibition of renal organic anion transporters (OATs).

Authors:  Xiaokui Huo; Qiang Meng; Changyuan Wang; Yanna Zhu; Zhihao Liu; Xiaodong Ma; Xiaochi Ma; Jinyong Peng; Huijun Sun; Kexin Liu
Journal:  Acta Pharm Sin B       Date:  2019-02-18       Impact factor: 11.413

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.